LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Corcept Therapeutics Inc

Aperta

SettoreSettore sanitario

75.34 3.35

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

71.79

Massimo

75.09

Metriche Chiave

By Trading Economics

Entrata

-9.8M

21M

Vendite

-25M

157M

P/E

Media del settore

62.73

56.602

EPS

0.169

Margine di Profitto

13.069

Dipendenti

500

EBITDA

-22M

3.4M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+95.16% upside

Dividendi

By Dow Jones

Utili prossimi

28 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-62M

7.7B

Apertura precedente

71.99

Chiusura precedente

75.34

Notizie sul Sentiment di mercato

By Acuity

26%

74%

59 / 382 Classifica in Healthcare

Corcept Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 mag 2025, 22:52 UTC

Utili
I principali Market Mover

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 mag 2025, 20:37 UTC

Notizie principali
Utili

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 mag 2025, 00:00 UTC

Discorsi di Mercato

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 mag 2025, 23:47 UTC

Discorsi di Mercato

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 mag 2025, 23:38 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

15 mag 2025, 23:38 UTC

Discorsi di Mercato

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 mag 2025, 23:14 UTC

Notizie principali

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 mag 2025, 22:46 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mag 2025, 21:58 UTC

Utili

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 mag 2025, 21:24 UTC

Utili

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 mag 2025, 20:56 UTC

Discorsi di Mercato

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 mag 2025, 20:54 UTC

Discorsi di Mercato
Utili

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 mag 2025, 20:54 UTC

Utili

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 mag 2025, 20:51 UTC

Utili

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 mag 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

15 mag 2025, 20:50 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 mag 2025, 20:50 UTC

Utili

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 mag 2025, 20:26 UTC

Notizie principali

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 mag 2025, 20:25 UTC

Utili

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Corcept Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

95.16% in crescita

Previsioni per 12 mesi

Media 138.25 USD  95.16%

Alto 145 USD

Basso 131 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Corcept Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

4

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

59 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.